OK, try this paragraph then
OK, so how does a cohort of 100s who are on a good SOC fare 60% better in relation to heart attacks and strokes in the class 2 cohort after one injection to healthy heart muscle 30 months later than compared to a cohort of 100s who are just on the SOC?
FDA must have figured it was more than just good patient selection to ask for an identification of the highest risk group in those 100s after the trial completed.
Silviu Itescu The Legend, page-294
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
0.010(0.66%) |
Mkt cap ! $1.741B | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.54 | $1.48 | $5.605M | 3.713M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 55197 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.53 | 29782 | 3 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |